Overview

Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epilepsy Patients

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the pharmacokinetics, safety, and tolerability of OXC XR as adjunctive therapy in pediatric subjects with refractory partial epilepsy.
Phase:
Phase 1
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.
Treatments:
Carbamazepine
Oxcarbazepine